Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. (ATOS) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ATOS · as of Jun 9, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Atossa Therapeutics, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
ATOS insider buying and selling by quarter
ATOS insider selling · ATOS insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · ATOS ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
ATOS executive sell shares · ATOS board member insider trading · ATOS insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 12, 2026 | Steinhart Richard I Director | Award | 10,000 | — | Form 4 |
| May 12, 2026 | Chen Shu-Chih Director | Award | 10,000 | — | Form 4 |
| May 12, 2026 | Remmel H. Lawrence Director | Award | 10,000 | — | Form 4 |
| May 12, 2026 | Finn Jonathan Director | Award | 10,000 | — | Form 4 |
| May 12, 2026 | Galli Stephen J Director | Award | 10,000 | — | Form 4 |
| May 12, 2026 | Cigler Tessa Director | Award | 10,000 | — | Form 4 |
| Mar 27, 2026 | QUAY STEVEN C President & CEO · Director | Award | 65,000 | — | Form 4 |
| Mar 26, 2026 | Daniel Mark James CFO | Award | 63,000 | — | Form 4 |
| Jan 20, 2026 | QUAY STEVEN C President & CEO · Director | Award | 325,203 | — | Form 4 |
| May 21, 2025 | QUAY STEVEN C President & CEO · Director | Purchase | 11,239 | $10K | Form 4 |
| Mar 26, 2025 | Remmel H. Lawrence Director | Purchase | 10,000 | $7K | Form 4 |
| Apr 10, 2024 | Finn Jonathan Director | Purchase | 25,000 | $44K | Form 4 |
| Nov 15, 2023 | WEAVER GREGORY L Former EVP, CFO, & Director | Sale | 50,000 | $33K | Form 4 |
| Jun 20, 2023 | WEAVER GREGORY L EVP & CFO · Director | Purchase | 50,000 | $49K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Option | 70,000 | $119K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Other | 57,084 | $365K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Option | 45,000 | $113K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Option | 45,000 | $107K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Option | 4,581 | $26K | Form 4 |
| Jul 2, 2021 | WEAVER GREGORY L Director | Sale | 107,497 | $600K | Form 4 |
QUAY STEVEN C
President & CEO · Director
Date
Mar 27
Shares
65,000
Price
—
Value
—
QUAY STEVEN C
President & CEO · Director
Date
Jan 20
Shares
325,203
Price
—
Value
—
QUAY STEVEN C
President & CEO · Director
Date
May 21
Shares
11,239
Price
$0.88
Value
$10K
WEAVER GREGORY L
Former EVP, CFO, & Director
Date
Nov 15
Shares
50,000
Price
$0.65
Value
$33K
WEAVER GREGORY L
EVP & CFO · Director
Date
Jun 20
Shares
50,000
Price
$0.97
Value
$49K
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ATOS insider trading
ATOS insider trades
Atossa Therapeutics, Inc. (ATOS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including QUAY STEVEN C (President & CEO · Director), Steinhart Richard I (Director), Chen Shu-Chih (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. ATOS insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Atossa Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ATOS insider trading · 5 questionsThe insiders of Atossa Therapeutics, Inc. (ATOS) include executives and directors such as QUAY STEVEN C (President & CEO · Director), Steinhart Richard I (Director), Chen Shu-Chih (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026